Evidence Grade A — Regulatory approved. 91 published studies. 10 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Bremelanotide (sold as Vyleesi) is an as-needed injectable treatment for low sexual desire in premenopausal women — specifically for a condition called HSDD (hypoactive sexual desire disorder) where persistently low desire causes personal distress. Unlike hormonal treatments, it works through the brain's melanocortin system to help activate the neural pathways involved in sexual desire. It was developed from the same family of research that produced the unregulated tanning peptides.
Bremelanotide is also known by these brand and alternate names:
91 published studies: 63 human, 5 animal, 1 in-vitro, 50 reviews
Bremelanotide is marketed as Vyleesi (approved June 2019). It is indicated for premenopausal women with acquired, generalised HSDD. Administered as a self-injection using an autoinjector, with a maximum of one dose per 24 hours and no more than eight doses per month.
In clinical trials, approximately 25% of women reported meaningful improvement in sexual desire (compared to 17% on placebo). The most common side effects are nausea (40%), flushing, and headache — the nausea has been a significant barrier to uptake. Bremelanotide can cause transient blood pressure increases and skin darkening with repeated use. Commercial adoption has been limited by the injection requirement, modest efficacy over placebo, and the nausea profile.
Unlike treatments that work on blood flow or hormones, bremelanotide acts in the brain. It activates melanocortin-4 receptors in areas of the brain involved in sexual desire and arousal, modulating the dopamine pathways that underpin sexual motivation. This central mechanism is fundamentally different from medications like sildenafil (Viagra), which work peripherally on blood vessels. The melanocortin system's role in sexual function was actually discovered accidentally during tanning peptide research, when early clinical subjects reported unexpected effects on sexual arousal.
In two clinical trials, about 25% of women on bremelanotide reported a meaningful improvement in sexual desire, compared to 17% on placebo — a statistically significant but modest difference. Importantly, there was no significant increase in the number of satisfying sexual events, only in the desire and distress measures. Nausea is the most prominent side effect, reported by 40% of patients, and was the main reason people stopped using it. Real-world reception has been mixed. Some users report dramatic improvements, while others experience nausea severe enough to outweigh any benefit. The injection requirement (self-administered at least 45 minutes before anticipated activity), limited to eight doses per month, has also been a practical barrier. Other concerns include transient blood pressure increases and the possibility of permanent skin darkening with repeated use. Commercial uptake has been limited. Bremelanotide's origins as a derivative of Melanotan II connect it to the broader research peptide space, though it is the only product from that lineage with full regulatory approval.
PeptideTrace tracks 10 registered clinical trials for Bremelanotide sourced from ClinicalTrials.gov.
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
FDA ORIG 1
FDA SUPPL 2
Bremelanotide is a cyclic 7-amino-acid peptide and a metabolite of Melanotan II. It activates melanocortin-4 (MC4R) and melanocortin-3 (MC3R) receptors. It is the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women that acts on central nervous system pathways.
Bremelanotide activates MC4R and MC3R in the hypothalamus and limbic system, modulating dopaminergic pathways involved in sexual desire and arousal. It acts centrally (not peripherally like PDE5 inhibitors). The melanocortin system's role in sexual function was discovered serendipitously during Melanotan II tanning peptide trials when male subjects reported spontaneous erections. Bremelanotide is the clinically refined derivative of this observation.
Bremelanotide is marketed as Vyleesi (approved June 21, 2019, now marketed by Cosette Pharmaceuticals). Indicated for premenopausal women with acquired, generalized HSDD. Administered as a PRN subcutaneous autoinjector (1.75 mg) at least 45 minutes before anticipated sexual activity, with a maximum of 8 doses per month. The RECONNECT trials (N=1,247) showed statistically significant but modest improvements in sexual desire (FSFI-D: +0.35 vs placebo) and reduced distress (FSDS-DAO: −0.33). The GAQ showed ~58% responder rate versus ~36% placebo. Nausea occurred in approximately 40% of patients.
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Kisspeptin-54 has no marketing authorisation. Phase II trials conducted primarily at Imperial College London have investigated its use as an IVF oocyte maturation trigger. One trial (60 patients) reported 95% oocyte maturation with zero cases of ovarian hyperstimulation syndrome. Kisspeptin-54 has a more advanced clinical evidence base than kisspeptin-10, with multiple Phase II studies in reproductive medicine. Its potential advantage over conventional IVF triggers relates to a lower risk of the serious complication of ovarian hyperstimulation. Clinical development is ongoing in academic settings. No Phase III trials have been completed.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Evidence Reviews
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
